Clinical Trial Update: Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating a breast cancer vaccine in combination with pembrolizumab for persistent, recurrent, or metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Breast cancer vaccine (experimental)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN